Anuh Pharma
78.79
-0.78(-0.98%)
Market Cap₹789.66 Cr
PE Ratio20.50
IndustryHealthcare
Company Performance:
1D-0.98%
1M-3.05%
6M-27.21%
1Y-29.29%
5Y-29.29%
View Company Insightsright
More news about Anuh Pharma
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
Anuh Pharma
78.79
-0.78
(-0.98%)
1 Year Returns:-29.29%
Industry Peers
Sun Pharmaceutical
1,807.20
(+1.22%)
Divis Laboratories
6,430.00
(+2.15%)
Torrent Pharmaceuticals
3,799.00
(+0.12%)
Cipla
1,512.30
(+1.44%)
Dr Reddys Laboratories
1,273.50
(+1.81%)
Lupin
2,081.80
(+1.28%)
Zydus Life Science
922.55
(-0.11%)
Mankind Pharma
2,166.80
(+0.83%)
Aurobindo Pharma
1,172.20
(-0.03%)
Alkem Laboratories
5,626.00
(+0.49%)